Compositions and methods for antigen-specific tolerance
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Universite De Nantes, Oniris
InventorsIgnacio ANEGON, Philippe BLANCOU, Thomas SIMON, Julien POGU
Life of this patent
Estimating the term…
Abstract
The invention is in the field of immunotherapy. More particularly, the invention provides a composition comprising a Heme Oxygenase-1 (HO-1) and antigens. Also provided herein are methods of administering the compositions of the invention by subcutaneous, intradermal or topical administration in a patient for inducing antigen-specific tolerance.
Claims21
A method for inducing immune tolerance in a patient suffering from or at risk of a condition related to immune tolerance, comprising
- administering to the patient a therapeutically effective amount of a composition comprising (i) a Heme Oxygenase-1 (HO-1) inducer and (ii) at least one pathogenic antigen involved in the condition,
- wherein the composition is administrated topically or intradermally to a patient's skin of the patient.
(canceled)
A method for preventing or reducing transplant rejection in a patient in need thereof, comprising a step of
- administering to the patient a therapeutically effective amount of a composition comprising (i) a Heme Oxygenase-1 (HO-1) inducer and (ii) at least one pathogenic antigen relevant to the transplant,
- wherein the composition is administrated topically or intradermally to skin of the patient,
- and wherein the pathogenic antigen is not insulin.
A method for preventing or treating an autoimmune disease, an unwanted immune response against proteins expressed in the course of gene therapy or therapeutic proteins, and/or an allergy in a patient in need thereof, comprising
- administering to the patient a therapeutically effective amount of a composition comprising (i) a Heme Oxygenase-1 (HO-1) inducer and (ii) at least one pathogenic antigen involved in the autoimmune disease, the unwanted immune response or the allergy,
- wherein the composition is administrated topically or intradermally to skin of the patient,
- and wherein the pathogenic antigen is not insulin.
(canceled)
An in vitro or ex vivo method for generating a population of tolerogenic antigen-presenting cells (APCs) specific for an antigen of interest, comprising a step of culturing a population of APCs with a culture medium comprising a heme oxygenase-1 (HO-1) inducer and said antigen of interest.
Dependencies are inferred from the claim text.